Targeting the IL33-NLRP3 axis improves therapy for experimental cerebral malaria.

Institutions FC
Health Innovation Manchester, United Kingdom (UK) 0.76
Division of Infectious Diseases and Immunology, UMass Medical School, United States of America (USA) 0.12
Department of Parasitology, LSTM, United Kingdom (UK) 0.06
Centre for Immunobiology, University of Glasgow, United Kingdom (UK) 0.03
School of Biology and Basic Medical Sciences, Soochow University, China 0.03

Return